IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 429.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,133 shares of the company's stock after acquiring an additional 19,575 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd's holdings in Tempus AI were worth $815,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of TEM. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI in the 4th quarter worth about $34,000. Prestige Wealth Management Group LLC lifted its stake in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. First Horizon Advisors Inc. lifted its position in shares of Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock valued at $55,000 after buying an additional 1,108 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Tempus AI during the fourth quarter worth about $67,000. Finally, IFP Advisors Inc purchased a new position in Tempus AI during the 4th quarter valued at about $76,000. Institutional investors and hedge funds own 24.22% of the company's stock.
Tempus AI Stock Up 0.9 %
Shares of Tempus AI stock opened at $48.24 on Tuesday. The stock's 50 day simple moving average is $58.64 and its 200-day simple moving average is $51.58. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45.
Analyst Ratings Changes
TEM has been the topic of a number of recent research reports. Wolfe Research cut shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Needham & Company LLC raised their target price on Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Piper Sandler dropped their target price on Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and increased their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $61.18.
Get Our Latest Report on TEM
Insider Transactions at Tempus AI
In other Tempus AI news, major shareholder Bradley A. Keywell sold 170,720 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total value of $6,052,024.00. Following the sale, the insider now owns 15,993,729 shares of the company's stock, valued at $566,977,693.05. This represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew Polovin sold 13,135 shares of Tempus AI stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total value of $603,947.30. Following the sale, the executive vice president now owns 154,171 shares of the company's stock, valued at approximately $7,088,782.58. This represents a 7.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,598,969 shares of company stock valued at $317,194,162.
About Tempus AI
(
Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Articles
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
